Search results for "vaccines"

showing 10 items of 554 documents

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease

2021

(1) Background: COVID-19 vaccination campaigns offer the best hope of controlling the pandemic. However, the fast production of COVID-19 vaccines has caused concern among the general public regarding their safety and efficacy. In particular, patients with chronic illnesses, such as celiac disease (CD), may be more fearful. Information on vaccine hesitancy plays a pivotal role in the development of an efficient vaccination campaign. In our study, we aimed to evaluate COVID-19 vaccine hesitancy among Italian CD patients. (2) Methods: an anonymous questionnaire was sent to CD patients followed at our tertiary referral center for CD in Milan, Italy. Patients were defined as willing, hesitant an…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ImmunologyCOVID-19 vaccinesDiseaseArticle03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryPandemicMedicinePharmacology (medical)Adverse effectPharmacologyResponse rate (survey)business.industryRCOVID-19Odds ratiovaccinesConfidence intervalVaccinationInfectious Diseases030220 oncology & carcinogenesisMedicinevaccine hesitancy030211 gastroenterology & hepatologybusinessCOVID-19 vaccineceliac diseaseVaccines
researchProduct

Epidemiological and virological studies into the poliomyelitis in Valencia (1959-1969)

2009

Studies into the polio virus began in Valencia in 1959 with the work undertaken by the microbiologist Vicente Sanchis-Bayarri Vaillant. After his education at the Rochester University and at the Pasteur Institute, Sanchis-Bayarri Vaillant established a laboratory of cell cultures at the Faculty of Medicine in Valencia, where he developed a new diagnostic technique for the poliomyelitis virus. In addition, epidemiological studies were carried out both prior to and post the 1963 vaccination campaign, which proved that Sabin’s oral vaccine was both effective and safe for use.

medicine.medical_specialtyEpidemiologyUNESCO::LINGÜÍSTICA::Lingüística aplicada::DocumentaciónPoliomielitisPoliomelitiscomplex mixtures:LINGÜÍSTICA::Lingüística aplicada::Documentación [UNESCO]History and Philosophy of ScienceCampañas de vacunaciónAZ20-999medicinePolio virusEpidemiologíaHistory of medicine. Medical expeditionsR131-687Poliomielitis; Poliovirus; Vacunas de la polio; Campañas de vacunación; Epidemiologíabusiness.industryPolio vaccinesPoliovirus Vaccinesmedicine.diseaseVaccination campaignsPoliomyelitisVaccinationPoliomyelitis virusPoliovirusVaccination CampaignsVacunas de la polioFamily medicinePolio virusHistory of scholarship and learning. The humanitiesbusinessPoliomyelitis
researchProduct

Knowledge about infection with human papillomavirus: a systematic review.

2007

Abstract Objective. Human papillomavirus (HPV) is a necessary cause of cervical cancer and genital warts. The aim of this systematic literature review was to provide an overview of knowledge about HPV infection among the public, students, patients and health professionals. Method. PubMed searches were performed and the results of studies were reported by age, gender, study population, country, recruitment score and year of study conduct. The recruitment score covered the mode of recruitment, study size and response rate. Results. We included 39 studies published between 1992 and 2006 covering a total of 19,986 participants. The proportion of participants who had heard of HPV varied from 13%…

medicine.medical_specialtyHealth Knowledge Attitudes PracticeEpidemiologyPopulationUterine Cervical NeoplasmsGenital wartsmedicineHumansPapillomavirus VaccinesRisk factoreducationPapillomaviridaeGynecologyCervical cancerResponse rate (survey)education.field_of_studybusiness.industryPapillomavirus InfectionsPublic Health Environmental and Occupational HealthHPV infectionvirus diseasesmedicine.diseaseSystematic reviewCondylomata AcuminataFamily medicinePopulation studyFemalebusinessPreventive medicine
researchProduct

HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)

2020

Human papillomavirus (HPV) related cervical cancer represents an issue of public health priority. The World Health Organization recommended the introduction of HPV vaccination in all national public programs. In Europe, vaccines against HPV have been available since 2006. In Italy, vaccination is recommended and has been freely offered to all young girls aged 11 years since 2008. Three prophylactic HPV vaccines are available against high- and low-risk genotypes. The quadrivalent vaccine contains protein antigens for HPV 6, 11, 16, and 18. The bivalent vaccine includes antigens for HPV 16 and 18. The nonavalent vaccine was introduced in 2014, and it targets HPV types 6, 11, 16, 18, 31, 33, 4…

medicine.medical_specialtyPathologycervical cancerprimary preventionImmunologylcsh:MedicineReviewHPV vaccinescervical intraepithelial neoplasiaCervical intraepithelial neoplasia03 medical and health sciences0302 clinical medicineDrug DiscoverymedicinePharmacology (medical)030212 general & internal medicineYoung adulthuman papillomavirusHPV vaccinePharmacologyColposcopyCervical cancermedicine.diagnostic_testbusiness.industryPublic healthlcsh:Rmedicine.diseaseVaccinationClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAInfectious Diseases030220 oncology & carcinogenesisbusinessVaccines
researchProduct

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

2014

Introduction: In 2009, two cases of seizures in adolescents following quadrivalent human papillomavirus vaccine (qHPV) administration generated important media attention, and adversely affected public trust in this vaccine. Our objectives were to describe suspected adverse reactions (SARs) reported to the Pharmacovigilance Centre in the Valencian Community (PCVC) after administration of HPV vaccine, and to compare reporting rates of syncope and seizures following this vaccine with those of other vaccines administered to girls aged 13–15 years. Materials and methods: Descriptive study of SARs reported following administration of this vaccine to the PCVC between 2007 and 2011. Results: The cl…

medicine.medical_specialtyPediatricsHuman papillomavirusTime FactorsAdolescentVirus del papiloma humanoVaccines AdministeredHuman papillomavirus vaccinePediatricsRJ1-570Valencian communitySyncopeReporting ratePharmacovigilanceHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18SeizuresManagement of Technology and InnovationPharmacovigilanceMedicineHumansRetrospective StudiesbiologyVacunabusiness.industryReacción adversaSyncope (genus)PharmacovigitanceTasa de notificaciónbiology.organism_classificationSurgeryVaccinationFarmacovigilanciaSpainFemalebusinessAdverse reactionsVaccineAnales de pediatria (Barcelona, Spain : 2003)
researchProduct

Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs

2020

Brazil; Chickenpox Vaccine; Humans; Immunization Programs; Public Health; Vaccination; Chickenpox; Viral Vaccines.

medicine.medical_specialtyVaricella vaccineMEDLINESettore MED/42 - Igiene Generale E ApplicataScientific evidenceChickenpox VaccineChickenpoxmedicineHumansChickenpox VaccineViral Vaccines.Immunization Programsbusiness.industryImmunization ProgramPublic healthViral VaccineVaccinationlcsh:RJ1-570Viral Vaccineslcsh:PediatricsVaccinationFamily medicinePediatrics Perinatology and Child HealthPublic HealthbusinessBrazilHumanJornal de Pediatria
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct